E3S Web Conf.
Volume 267, 20217th International Conference on Energy Science and Chemical Engineering (ICESCE 2021)
|Number of page(s)||10|
|Section||Environmental Chemistry Research and Chemical Preparation Process|
|Published online||04 June 2021|
Innovative immunotherapy targeting at PD-1/PD-L1 signaling pathway: mechanism, efficacy and safety analysis of monotherapy and combination therapies in non-small cell lung cancer (NSCLC) treatment
1 Liaoning Province Shiyan High School, Shenyang, Liaoning Province 110010, China
2 School of International Education, Beijing University of Chemical Technology, Beijing 102200, P.R. China
Lung cancer remains a leading cause of cancer-related mortality worldwide with a poor prognosis. Conventional therapies are most commonly used in all kinds of treatment because of their relatively high efficacy in killing tumor cells at first. However, as treatment time increases, this efficacy would gradually decrease, along with unavoidable and growing resistance and multiple and serious side effects. At this point, immunotherapy, including anti-PD-1 and anti-PD-L1 antibodies, renders an innovative and more effective way to take advantage of our own immune response to kill cancer cells. It is confirmed to have greater efficacy and safety of immunotherapy over conventional therapies in various cancer treatments, including non-small cell cancer. Combining conventional therapies can also lead to synergistic effects in controlling and killing cancer cells. The purpose of this summary is to verify the efficacy and safety of immune checkpoint inhibitor monotherapy and the synergistic effects of combination therapy with chemotherapy and radiotherapy. This review will introduce the mechanism, efficacy, and safety of immune checkpoint inhibitor monotherapy and combination therapies with chemotherapy and radiotherapy via a summary and interpretation of related preclinical and clinical trials.
© The Authors, published by EDP Sciences, 2021
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.